• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

胆汁代谢物作为肝门部胆管癌的诊断生物标志物。

Bile metabolites as diagnostic biomarkers for perihilar cholangiocarcinoma.

机构信息

Department of General Surgery, The First Affiliated Hospital of Bengbu Medical College, No. 287, Changhuai Road, Longzihu District, Bengbu, 233000, Anhui, China.

出版信息

Sci Rep. 2023 Feb 23;13(1):3177. doi: 10.1038/s41598-023-27603-6.

DOI:10.1038/s41598-023-27603-6
PMID:36823159
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9950048/
Abstract

It is difficult to directly obtain pathological diagnosis of perihilar cholangiocarcinoma (pCCA). Analysis of bile in the pCCA microenvironment, based on metabolomics and statistical methods, can help in clinical diagnosis. Clinical information, bile samples, blood liver function, blood CA199, CEA, and other indicators were collected from 33 patients with pCCA and 16 patients with gallstones. Bile samples were analyzed using untargeted metabolomics methods. A combination of multivariate and univariate analyses were used to screen for potential differential metabolites Through Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment and differential metabolite remodeling, we explored changes in the pCCA pathway and potential therapeutic targets. There were significant differences in patient blood TBIL, ALT, AST, TBA, CA19-9, and CEA indices (p < 0.05, |log2(fc)| ≥ 1) between two groups. A significant correlation was found between these different indicators by Spearman's analysis. The clinical parameters were correlated with mass-to-charge ratios of 305 (Positive Ion Mode, POS) and 246 (Negative Ion Mode, NEG) in the metabolic group (|r| ≥ 0.7, P ≤ 10). The result of this study indicated that bile untargeted metabolomics combined with statistical analysis techniques may be used for diagnose and treatment of pCCA.

摘要

难以直接获得肝门部周围性胆管癌(pCCA)的病理诊断。基于代谢组学和统计学方法分析 pCCA 微环境中的胆汁,可以辅助临床诊断。本研究共纳入 33 例 pCCA 患者和 16 例胆囊结石患者,采集患者临床资料、胆汁样本、血肝功能、血 CA199、CEA 等指标,采用非靶向代谢组学方法分析胆汁样本。采用多元和单变量分析相结合的方法筛选潜在差异代谢物。通过京都基因与基因组百科全书(KEGG)富集和差异代谢物重塑,探讨 pCCA 通路变化和潜在治疗靶点。两组患者的血液 TBIL、ALT、AST、TBA、CA19-9 和 CEA 指标存在显著差异(p < 0.05,|log2(fc)| ≥ 1)。Spearman 分析发现这些不同指标之间存在显著相关性。代谢组学中代谢物的临床参数与 305(正离子模式,POS)和 246(负离子模式,NEG)的质荷比呈正相关(|r| ≥ 0.7,P ≤ 10)。本研究结果表明,胆汁非靶向代谢组学联合统计分析技术可能用于 pCCA 的诊断和治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d5b/9950048/58d2c2f868b7/41598_2023_27603_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d5b/9950048/c215da4642c0/41598_2023_27603_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d5b/9950048/228265c0b614/41598_2023_27603_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d5b/9950048/ea1306c6e99d/41598_2023_27603_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d5b/9950048/cc6fe4818165/41598_2023_27603_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d5b/9950048/7a9275f492cb/41598_2023_27603_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d5b/9950048/58d2c2f868b7/41598_2023_27603_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d5b/9950048/c215da4642c0/41598_2023_27603_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d5b/9950048/228265c0b614/41598_2023_27603_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d5b/9950048/ea1306c6e99d/41598_2023_27603_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d5b/9950048/cc6fe4818165/41598_2023_27603_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d5b/9950048/7a9275f492cb/41598_2023_27603_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d5b/9950048/58d2c2f868b7/41598_2023_27603_Fig6_HTML.jpg

相似文献

1
Bile metabolites as diagnostic biomarkers for perihilar cholangiocarcinoma.胆汁代谢物作为肝门部胆管癌的诊断生物标志物。
Sci Rep. 2023 Feb 23;13(1):3177. doi: 10.1038/s41598-023-27603-6.
2
NLCECA score: a serum inflammatory-tumor biomarker score to predict survival of advanced perihilar cholangiocarcinoma after hepatic arterial infusion chemotherapy.NLCECA 评分:一种血清炎症-肿瘤生物标志物评分,可预测肝动脉灌注化疗后晚期肝门部胆管癌的生存情况。
Sci Rep. 2024 Feb 23;14(1):4466. doi: 10.1038/s41598-024-53883-7.
3
Cystic duct carcinoma and type I/II perihilar cholangiocarcinoma: Clinicopathological features and a new differential diagnosis model.胆囊管癌与I/II型肝门周围胆管癌:临床病理特征及一种新的鉴别诊断模型
Eur J Surg Oncol. 2023 Dec;49(12):107099. doi: 10.1016/j.ejso.2023.107099. Epub 2023 Sep 26.
4
Cholangiocarcinoma miscoding in hepatobiliary centres.肝胆中心胆管癌错配。
Eur J Surg Oncol. 2021 Mar;47(3 Pt B):635-639. doi: 10.1016/j.ejso.2020.09.039. Epub 2020 Oct 1.
5
Can the Limits of Liver Transplantation Be Expanded in Perihilar Cholangiocarcinoma?肝门部胆管癌的肝移植极限能否扩大?
J Gastrointest Cancer. 2022 Dec;53(4):1104-1112. doi: 10.1007/s12029-021-00735-6. Epub 2021 Nov 5.
6
A new clinically based staging system for perihilar cholangiocarcinoma.一种基于临床的肝门部胆管癌新分期系统。
Am J Gastroenterol. 2014 Dec;109(12):1881-90. doi: 10.1038/ajg.2014.327. Epub 2014 Nov 11.
7
Galanin System in the Human Bile Duct and Perihilar Cholangiocarcinoma.人类胆管中的甘丙肽系统与肝门周围胆管癌。
Cells. 2023 Jun 21;12(13):1678. doi: 10.3390/cells12131678.
8
ASO Author Reflections: Classification of Intrahepatic Cholangiocarcinoma into Perihilar versus Peripheral Subtype.ASO作者反思:肝内胆管癌分为肝门部与外周型亚型的分类
Ann Surg Oncol. 2024 Feb;31(2):1274-1275. doi: 10.1245/s10434-023-14547-4. Epub 2023 Nov 22.
9
ASO Author Reflections: Adequate Nodal Classification for Perihilar Cholangiocarcinoma.ASO作者反思:肝门周围胆管癌的充分淋巴结分类
Ann Surg Oncol. 2023 Jul;30(7):4318-4319. doi: 10.1245/s10434-023-13418-2. Epub 2023 Mar 31.
10
[Correlation between clinicopathological features and CA19-9/CEA in patients with extrahepatic cholangiocarcinoma].[肝外胆管癌患者临床病理特征与CA19-9/CEA的相关性]
Zhonghua Zhong Liu Za Zhi. 2014 Sep;36(9):662-6.

引用本文的文献

1
Machine learning-driven prediction of immune checkpoint inhibitor responses against cholangiocarcinoma: a bile biopsy perspective.机器学习驱动的针对胆管癌的免疫检查点抑制剂反应预测:胆汁活检视角
Front Immunol. 2025 Jun 16;16:1614683. doi: 10.3389/fimmu.2025.1614683. eCollection 2025.
2
Investigating the causal relationship between the plasma lipidome and cholangiocarcinoma mediated by immune cells: a mediation Mendelian randomization study.探究免疫细胞介导的血浆脂质组与胆管癌之间的因果关系:一项中介孟德尔随机化研究
Sci Rep. 2025 Feb 17;15(1):5807. doi: 10.1038/s41598-025-90140-x.
3
The Search for Risk, Diagnostic, and Prognostic Biomarkers of Cholangiocarcinoma and Their Biological and Clinicopathologic Significance.

本文引用的文献

1
Greater than or equal to 8 mm is a safe diameter of common bile duct for primary duct closure: single-arm meta-analysis and systematic review.胆总管直径大于或等于 8 毫米是行胆总管一期缝合的安全直径:单臂荟萃分析和系统评价。
Clin J Gastroenterol. 2022 Jun;15(3):513-521. doi: 10.1007/s12328-022-01615-7. Epub 2022 Mar 5.
2
Disordered farnesoid X receptor signaling is associated with liver carcinogenesis in Abcb11-deficient mice.法尼醇 X 受体信号紊乱与 Abcb11 缺陷小鼠的肝癌发生有关。
J Pathol. 2021 Dec;255(4):412-424. doi: 10.1002/path.5780. Epub 2021 Sep 28.
3
Infigratinib Is a Reversible Inhibitor and Mechanism-Based Inactivator of Cytochrome P450 3A4.
胆管癌风险、诊断及预后生物标志物的探索及其生物学和临床病理意义
Am J Pathol. 2025 Mar;195(3):422-436. doi: 10.1016/j.ajpath.2024.06.013. Epub 2024 Aug 3.
4
Unveiling the potential of strain elastography in perihilar cholangiocarcinoma biopsies.揭示应变弹性成像在肝门部胆管癌活检中的潜力。
Abdom Radiol (NY). 2024 Sep;49(9):3143-3148. doi: 10.1007/s00261-024-04255-2. Epub 2024 Apr 1.
英菲格拉替尼是一种细胞色素P450 3A4的可逆抑制剂和基于机制的失活剂。
Drug Metab Dispos. 2021 Sep;49(9):856-868. doi: 10.1124/dmd.121.000508. Epub 2021 Jul 29.
4
The Clinical Management of Cholangiocarcinoma in the United States and Europe: A Comprehensive and Evidence-Based Comparison of Guidelines.美国和欧洲胆管癌的临床管理:指南的全面循证比较
Ann Surg Oncol. 2021 May;28(5):2660-2674. doi: 10.1245/s10434-021-09671-y. Epub 2021 Mar 1.
5
[FXR modulators and cholestatic diseases.].[法尼醇X受体调节剂与胆汁淤积性疾病。]
Recenti Prog Med. 2021 Feb;112(2):124-127. doi: 10.1701/3559.35373.
6
Bsep expression in hilar cholangiocarcinoma of rat model.大鼠模型肝内胆管细胞癌中 Bsep 的表达。
Sci Rep. 2021 Feb 3;11(1):2861. doi: 10.1038/s41598-021-82636-z.
7
Effect of Margin Status on Survival After Resection of Hilar Cholangiocarcinoma in the Modern Era of Adjuvant Therapies.在辅助治疗的现代时代,边缘状态对肝门部胆管癌切除术后生存的影响。
Am Surg. 2021 Sep;87(9):1496-1503. doi: 10.1177/0003134820973401. Epub 2020 Dec 21.
8
Liquid Biopsy of Bile based on Targeted Mass Spectrometry for the Diagnosis of Malignant Biliary Strictures.基于靶向质谱的胆汁液活检在恶性胆道狭窄诊断中的应用。
Clin Transl Sci. 2021 Jan;14(1):148-152. doi: 10.1111/cts.12890. Epub 2020 Oct 23.
9
Cholangiocarcinoma 2020: the next horizon in mechanisms and management.胆管癌 2020:机制和管理的新前沿。
Nat Rev Gastroenterol Hepatol. 2020 Sep;17(9):557-588. doi: 10.1038/s41575-020-0310-z. Epub 2020 Jun 30.
10
Patients with Cholangiocarcinoma Present Specific RNA Profiles in Serum and Urine Extracellular Vesicles Mirroring the Tumor Expression: Novel Liquid Biopsy Biomarkers for Disease Diagnosis.胆管癌患者的血清和尿液外泌体中存在特定的 RNA 谱,反映了肿瘤的表达:用于疾病诊断的新型液体活检生物标志物。
Cells. 2020 Mar 14;9(3):721. doi: 10.3390/cells9030721.